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Introduction paclitaxel at a dose level and schedule targeting tumor endothelium
The current standard treatment for advanced ovarian cancer is
the administration of paclitaxel in combination with a platinum-
containing agent. This regimen is effective, with a high clinical
response rate and prolonged progression-free and overall survival.1-3
Rosenberg et al demonstrated that weekly paclitaxel administration
was as effective as dosing every 3 weeks, with a better safety proﬁle
in patients with advanced ovarian cancer who were previously
treated with 1 platinum-containing regimen.4 Subsequently, many
studies have examined weekly paclitaxel therapy in recurrent ovarian
cancer, demonstrating tolerability and good activity.5,6 Weekly
schedules of chemotherapy may be preferential, as they allow for
dose modiﬁcations during the course of therapy and may avoid
severe toxicities that may occur following larger doses given every
3 weeks. Thus, the question arises regarding the utility of dose-
dense chemotherapy in upfront ovarian cancer. In particular,
bulky ovarian cancers are likely biologically heterogeneous with
both platinum-sensitive and platinum-resistant populations sug-
gesting utility for upfront dose-dense chemotherapy.
Discussion
In preclinical studies, noncytotoxic concentrations of paclitaxel
have been shown to inhibit angiogenesis through selective inhibition
of endothelial-cell migration and tube formation.7-9 The cytostatic
effect seems to be independent of mitotic arrest and is associated
with increase in dynamic instability, slowing the metaphase-to-
anaphase transition.10 Theoretically, even in tumors that have
acquired resistance to the cytotoxic effects of paclitaxel, this drug-
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metronomic chemotherapy would have increased efﬁcacy because
of the enhanced antiangiogenic and vascular-disrupting effect
when compared with that of conventional, every-3-week dosing.13
Furthermore, in mouse models, Chang et al found that the dose-
dense regimen had greater therapeutic effects than the maximum
tolerated dose, leading to the treatment of 14 patients with platinum-
resistant relapsed ovarian cancer. The authors suggest that dose-
dense administration spares the immune system from major toxicity
and modiﬁes the tumor microenvironment favoring immunogenic
tumor cell death through CD8þ T-cell activation and macrophage
recruitment, resulting in generation antitumor immunity.14
Although there is limited data in frontline primary advanced
ovarian cancer using weekly paclitaxel and carboplatin therapy, there
are some studies indicating feasibility. Sehouli et al conducted a phase
II that enrolled 129 patients to weekly paclitaxel and carboplatin
therapy and demonstrated achievability. However, they were not
able to show an improvement in progression-free (PFS) or overall
survival (OS).15 The most compelling evidence to date suggesting
that dose-dense weekly paclitaxel is more effective than paclitaxel
therapy every 3 weeks is from the Japanese Gynecologic Oncology
Group (JGOG). In a phase III trial by the JGOG, 631 women were
randomized to either standard carboplatin (area under the curve
[AUC] of 6 on day 1) and paclitaxel (180mg/m2 on day 1) given every
3 weeks versus carboplatin (AUC 6 on day 1) and weekly paclitaxel
(80 mg/m2 days 1, 8, and 15) given on a 3-week cycle. Both cycles
could be given up to 9 cycles. At a median follow-up of 29 months,
the dose-dense treatment demonstrated signiﬁcant improvement
in median PFS (28 vs. 17 months, hazard ratio [HR] for recurrence,
0.71; 95% CI, 0.57-0.98) as well as signiﬁcant improvement in
overall survival at 3 years (mortality HR, 0.75; 95% CI, 0.57-0.98).
This dose-dense therapy regimen did not require upfront optimal
cytoreduction and allowed for interval debulking surgery after 2 to
4 cycles of chemotherapy, secondary debulking or second-look sur-
gery after 6 cycles of chemotherapy, or both. Furthermore, about
half of the treatment cohort underwent suboptimal tumor debulkingClinical Ovarian and Other Gynecologic Cancer December 2012 - 51
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52 -with PFS analysis showing equal effect size in the suboptimal and
optimal groups.16 Collectively, these ﬁndings are important to
potentially improve PFS inwomenwith advanced ovarian cancer with
either optimal or suboptimal debulking efforts.
There are no studies that have shown beneﬁt of dose-dense
chemotherapy in the neoadjuvant chemotherapy (NACT) setting;
however, we can extrapolate from existing data that patients with
suboptimal cytoreduction who do worse than their optimal coun-
terparts with standard adjuvant chemotherapy may beneﬁt from
this dose-dense regimen. Vergote et al randomized 670 patients to
primary debulking versus NACT followed by interval debulking
surgery and showed that NACT followed by interval debulking sur-
gery was not inferior to primary debulking surgery.17 Furthermore, in
a largely suboptimal population, the NACT group had the same
outcome as that of every-3-week chemotherapy. In a large randomized
trial, the Gynecologic Cancer Cooperative Group of the European
Organization for Research and Treatment of Cancer (EORTC)
randomly assigned women with residual lesions> 1cm in diameter to
6 cycles of chemotherapy alone or 3 cycles of chemotherapy followed
by interval cytoreduction and 3 more cycles of chemotherapy.
Women who underwent a secondary attempt at debulking had
signiﬁcantly longer disease-free survival.17 Conversely, the Gyneco-
logicOncologyGroup (GOG) conducted a similar study (GOG152)
but did not conﬁrm a survival beneﬁt for interval cytoreduction.18 In
both studies, chemotherapywas given every 3weeks. Thus, in patients
with large-volume disease (more likely to receive NACT) and sub-
optimally debulked patients, chemotherapy given every 3 weeks does
not seem to improve survival compared with that of dose-dense
chemotherapy (JGOG). To address this question, GOG 262 was
initiated for women with suboptimally debulked ovarian cancer,
randomizing women to every-3-week paclitaxel therapy or dose-dense
weekly paclitaxel therapy in combination with carboplatin with or
without bevacizumab in treatment and consolidation.
Future studies examining dose-dense chemotherapy in a variety
of settings will help elucidate its role in the treatment of advanced
ovarian cancer. First, the major study indicating signiﬁcant survival
beneﬁt with dose-dense chemotherapy was performed in Asian pa-
tients only. Genotypes and phenotypes may represent important
determinants of drug efﬁcacy, and thus MITO-7 (Multicenter
Italian Trials in Ovarian Cancer) is under way, examining-dose
dense chemotherapy in a different population. Next, investigators
should consider dose-dense chemotherapy given in the NACT
setting. ICON8 (International Collaborative Ovarian Neoplasm) is a
3-arm, 3 stage trial randomizing patients in a 1:1:1 ratio to (arm 1)
carboplatin and paclitaxel on day 1 of a 21-day cycle versus (arm 2)
carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1,
8, and 15 of a 21-day cycle versus (arm 3) dose-fractionated weekly
carboplatin and dose-fractionated weekly paclitaxel on day 1, 8, and
15 of a 21 day cycle. All 3 arms will be given 6 cycles. Another
consideration is whether dose-dense chemotherapy can be effectively
given as intraperitoneal (IP) chemotherapy. Previous data fromGOG
172 using intravenous (I.V.)/IP chemotherapy following surgical
debulking in women with advanced ovarian cancer was more effective
than standard I.V. chemotherapy.18 However, this schema included a
dose-dense regimen in I.V./IP arm, which made it difﬁcult to deter-
mine whether the dose-dense regimen, route of administration, or
both resulted in the superior outcome. The survival data of dose-denseClinical Ovarian and Other Gynecologic Cancer December 2012I.V. chemotherapy is similar to that of the IP regimen, suggesting that
the improved outcome may be because paclitaxel was given more
frequently rather than due to direct peritoneal chemotherapy. To
address this question, the JGOG and Gynecologic Oncology Trial
and Investigations Consortium (JGOG 3019/GOTIC 001) opened
a phase III trial comparing IP carboplatin and I.V. carboplatin
administration, both with weekly dose-dense I.V. paclitaxel therapy.
Furthermore, GOG 252 is a phase III trial comparing 2 different IP
regimens with I.V. chemotherapy, with all 3 arms given with bev-
acizumab during chemotherapy and as consolidation. This study also
incorporates dose-dense paclitaxel in all 3 arms.
Conclusion
In conclusion, it is reasonable to presume that if these trials
conﬁrm the JGOG data, then weekly paclitaxel administration is
an appropriate strategy to consider in the standard treatment of
advanced ovarian cancer.Acknowledgments
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